share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q：2024財年三季報
美股SEC公告 ·  2024/11/13 02:31

Moomoo AI 已提取核心訊息

BeiGene reported Q3 2024 total revenue of $1.0 billion, up 28% year-over-year, driven by strong global BRUKINSA sales which grew 93% to $690.3 million. U.S. BRUKINSA revenue surged 87% to $503.7 million as it gained market share in CLL. Net loss narrowed to $121.4 million from $215.4 million profit last year, impacted by increased R&D and SG&A expenses.Operating expenses increased 16% to $951.4 million, with R&D expenses up 10% to $496.2 million due to advancing pipeline programs. SG&A expenses rose 25% to $455.2 million to support commercial expansion, though decreased as a percentage of product sales to 46% from 61%. Gross margin remained strong at 82.8% despite accelerated depreciation costs.The company continued global expansion with TEVIMBRA's U.S. commercial launch and positive CHMP opinions in Europe. Eight new molecular entities entered clinical development year-to-date, on track to achieve goal of 10+ by year-end. Cash position remained solid at $2.7 billion as of September 30, 2024.
BeiGene reported Q3 2024 total revenue of $1.0 billion, up 28% year-over-year, driven by strong global BRUKINSA sales which grew 93% to $690.3 million. U.S. BRUKINSA revenue surged 87% to $503.7 million as it gained market share in CLL. Net loss narrowed to $121.4 million from $215.4 million profit last year, impacted by increased R&D and SG&A expenses.Operating expenses increased 16% to $951.4 million, with R&D expenses up 10% to $496.2 million due to advancing pipeline programs. SG&A expenses rose 25% to $455.2 million to support commercial expansion, though decreased as a percentage of product sales to 46% from 61%. Gross margin remained strong at 82.8% despite accelerated depreciation costs.The company continued global expansion with TEVIMBRA's U.S. commercial launch and positive CHMP opinions in Europe. Eight new molecular entities entered clinical development year-to-date, on track to achieve goal of 10+ by year-end. Cash position remained solid at $2.7 billion as of September 30, 2024.
百濟神州報告2024年第三季度總營業收入爲10億人民幣，同比增長28%，主要受益於全球BRUKINSA銷售的強勁增長，銷售額增長93%，達到69030萬人民幣。美國BRUKINSA的營業收入激增87%，達到50370萬人民幣，市場份額在慢性淋巴細胞白血病（CLL）中不斷攀升。淨虧損縮小至12140萬人民幣，而去年爲21540萬人民幣的利潤，受研發和銷售及管理費用增加的影響。營業費用增加16%，達到95140萬人民幣，研發費用因開發管線項目的推進上漲10%，達到49620萬人民幣。銷售及管理費用支持商業擴展，增加25%，達到45520萬人民幣，但作爲產品銷售比例從61%下降至46%。毛利率儘管加速折舊成本依然保持強勁，達到82.8%。公司繼續全球擴展，TEVIMBRA在美國的商業推廣及歐洲的CHMP積極意見。迄今爲止，有八個新分子實體進入臨牀開發，有望在年底前達到10個以上的目標。截至2024年9月30日，現金狀況保持穩固，達到27億人民幣。
百濟神州報告2024年第三季度總營業收入爲10億人民幣，同比增長28%，主要受益於全球BRUKINSA銷售的強勁增長，銷售額增長93%，達到69030萬人民幣。美國BRUKINSA的營業收入激增87%，達到50370萬人民幣，市場份額在慢性淋巴細胞白血病（CLL）中不斷攀升。淨虧損縮小至12140萬人民幣，而去年爲21540萬人民幣的利潤，受研發和銷售及管理費用增加的影響。營業費用增加16%，達到95140萬人民幣，研發費用因開發管線項目的推進上漲10%，達到49620萬人民幣。銷售及管理費用支持商業擴展，增加25%，達到45520萬人民幣，但作爲產品銷售比例從61%下降至46%。毛利率儘管加速折舊成本依然保持強勁，達到82.8%。公司繼續全球擴展，TEVIMBRA在美國的商業推廣及歐洲的CHMP積極意見。迄今爲止，有八個新分子實體進入臨牀開發，有望在年底前達到10個以上的目標。截至2024年9月30日，現金狀況保持穩固，達到27億人民幣。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間